Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;16(10):556-577.
doi: 10.1038/s41574-020-0392-2. Epub 2020 Aug 27.

Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

André J Scheen  1   2
Affiliations
Review

Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus

André J Scheen. Nat Rev Endocrinol. 2020 Oct.

Abstract

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex. Sodium-glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic agents for T2DM. By targeting the kidney, they have a unique mechanism of action, which results in enhanced glucosuria, osmotic diuresis and natriuresis, thereby improving glucose control with a limited risk of hypoglycaemia and exerting additional positive effects such as weight loss and the lowering of blood pressure. Several outcome studies with canagliflozin, dapagliflozin or empagliflozin reported a statistically significant reduction in major cardiovascular events, hospitalization for heart failure and progression to advanced renal disease in patients with T2DM who have established atherosclerotic cardiovascular disease, several cardiovascular risk factors, albuminuric mild to moderate chronic kidney disease or heart failure. Current guidelines proposed a new paradigm in the management of T2DM, with a preferential place for SGLT2is, after metformin, in patients with atherosclerotic cardiovascular disease, heart failure and progressive kidney disease. Ongoing trials might extend the therapeutic potential of SGLT2is in patients with, but also without, T2DM. This Review provides an update of the current knowledge on SGLT2is, moving from their use as glucose-lowering medications to their new positioning as cardiovascular and renal protective agents.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tancredi, M. et al. Excess mortality among persons with type 2 diabetes. N. Engl. J. Med. 373, 1720–1732 (2015). - PubMed
    1. Bommer, C. et al. The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study. Lancet Diabetes Endocrinol. 5, 423–430 (2017). - PubMed
    1. Scheen, A. J. & Charbonnel, B. Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal. Diabetes Metab. 40, 176–185 (2014). - PubMed
    1. Kirkman, M. S., Mahmud, H. & Korytkowski, M. T. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes mellitus. Endocrinol. Metab. Clin. North. Am. 47, 81–96 (2018). - PubMed
    1. Lipska, K. J. et al. Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006-2013. Diabetes Care 40, 468–475 (2017). - PubMed

MeSH terms

Substances